US 10081626
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted A61KA61K31/439A61K31/46
Quick answer
US patent 10081626 (8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists) held by Theravance Biopharma R&D IP, LLC expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/485, A61K45/06